

Dong-Hwan Lee

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6549729/publications.pdf>

Version: 2024-02-01

30
papers

337
citations

933447
10
h-index

888059
17
g-index

31
all docs

31
docs citations

31
times ranked

521
citing authors

#	ARTICLE	IF	CITATIONS
1	Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 1353-1364.	3.0	6
2	The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation. <i>Acute and Critical Care</i> , 2022, 37, 177-184.	1.4	7
3	Predicting Antibiotic Effect of Vancomycin Using Pharmacokinetic/Pharmacodynamic Modeling and Simulation: Dense Sampling versus Sparse Sampling. <i>Antibiotics</i> , 2022, 11, 743.	3.7	4
4	Prospective Cohort Study of Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Adults on Extracorporeal Membrane Oxygenation. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, .	3.2	10
5	Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation. <i>Frontiers in Pharmacology</i> , 2021, 12, 768912.	3.5	8
6	Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation. <i>Pharmaceutics</i> , 2021, 13, 1861.	4.5	5
7	Impact of Sampling Period on Population Pharmacokinetic Analysis of Antibiotics: Why do You Take Blood Samples Following the Fourth Dose?. <i>Pharmaceutics</i> , 2020, 13, 249.	3.8	1
8	A new population pharmacokinetic model for vancomycin in patients with variable renal function: Therapeutic drug monitoring based on extended covariate model using CKDâ€EPI estimation. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2019, 44, 750-759.	1.5	16
9	1540. A Population Pharmacokinetic Model for Vancomycin in Korean Patients Receiving Extracorporeal Membrane Oxygenation Therapy: A Prospective Study. <i>Open Forum Infectious Diseases</i> , 2019, 6, S562-S562.	0.9	0
10	10-Phenyltriazoyl Artemisinin is a Novel P-glycoprotein Inhibitor that Suppresses the Overexpression and Function of P-glycoprotein. <i>Current Pharmaceutical Design</i> , 2019, 24, 5590-5597.	1.9	7
11	Nephrotoxicity of amikacin in noncritically ill patients. <i>Clinical Nephrology</i> , 2019, 92, 201-207.	0.7	4
12	Effect of pharmacokinetic model misspecification on antibiotic probability of target attainment predicted by Monte Carlo simulation. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2019, 57, 362-374.	0.6	4
13	Population Pharmacokinetic Analysis of Meropenem After Intravenous Infusion in Korean Patients With Acute Infections. <i>Clinical Therapeutics</i> , 2018, 40, 1384-1395.	2.5	9
14	Pharmacokinetics of Doripenem in Healthy Koreans and Monte Carlo Simulations to Explore Optimal Dosage Regimens in Patients With Normal and Enhanced Renal Function. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 425-434.	2.0	3
15	Population Pharmacokinetic Analysis of Doripenem after Intravenous Infusion in Korean Patients with Acute Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	9
16	Parameter estimation for sigmoid E_{\max} models in exposure-response relationship. <i>Translational and Clinical Pharmacology</i> , 2017, 25, 74.	0.9	7
17	Population Pharmacokineticâ€Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. <i>Clinical Therapeutics</i> , 2016, 38, 2610-2621.	2.5	8
18	Assessment of statistical power for covariate effects in data from phase I clinical trials. <i>Translational and Clinical Pharmacology</i> , 2015, 23, 31.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Development of a Pharmacokinetic Interaction Model for Co-administration of Simvastatin and Amlodipine. Drug Metabolism and Pharmacokinetics, 2014, 29, 120-128.	2.2	25
20	Population Pharmacokinetic Analysis of Diurnal and Seasonal Variations of Plasma Concentrations of Cilostazol in Healthy Volunteers. Therapeutic Drug Monitoring, 2014, 36, 771-780.	2.0	5
21	Pharmacokinetic Interaction Between Rosuvastatin and Olmesartan: A Randomized, Open-label, 3-period, Multiple-dose Crossover Study in Healthy Korean Male Subjects. Clinical Therapeutics, 2014, 36, 1159-1170.	2.5	14
22	Pharmacokinetic Interaction Between Rosuvastatin and Metformin in Healthy Korean Male Volunteers: A Randomized, Open-label, 3-period, Crossover, Multiple-dose Study. Clinical Therapeutics, 2014, 36, 1171-1181.	2.5	11
23	Pharmacokinetic Interaction Between Rosuvastatin and Telmisartan in Healthy Korean Male Volunteers: A Randomized, Open-label, Two-period, Crossover, Multiple-dose Study. Clinical Therapeutics, 2014, 36, 1147-1158.	2.5	25
24	Pharmacokinetics of Rosuvastatin/Olmesartan Fixed-Dose Combination: A Single-Dose, Randomized, Open-Label, 2-Period Crossover Study in Healthy Korean Subjects. Clinical Therapeutics, 2013, 35, 915-922.	2.5	12
25	Pharmacokinetic Comparison of 2 Fixed-Dose Combination Tablets of Amlodipine and Valsartan in Healthy Male Korean Volunteers: A Randomized, Open-Label, 2-Period, Single-Dose, Crossover Study. Clinical Therapeutics, 2013, 35, 934-940.	2.5	9
26	Pharmacokinetic Comparison of an Orally Disintegrating Film Formulation With a Film-Coated Tablet Formulation of Sildenafil in Healthy Korean Subjects: A Randomized, Open-Label, Single-Dose, 2-Period Crossover Study. Clinical Therapeutics, 2013, 35, 205-214.	2.5	14
27	Effect of <i>HMGCR</i> Variant Alleles on Low-Density Lipoprotein Cholesterol-Lowering Response to Atorvastatin in Healthy Korean Subjects. Journal of Clinical Pharmacology, 2012, 52, 339-346.	2.0	26
28	Rifampin Enhances the Glucose-Lowering Effect of Metformin and Increases OCT1 mRNA Levels in Healthy Participants. Clinical Pharmacology and Therapeutics, 2011, 89, 416-421.	4.7	75
29	Pharmacokinetic Comparison of Sustained- and Immediate-Release Oral Formulations of Cilostazol in Healthy Korean Subjects: A Randomized, Open-Label, 3-Part, Sequential, 2-Period, Crossover, Single-Dose, Food-Effect, and Multiple-Dose Study. Clinical Therapeutics, 2011, 33, 2038-2053.	2.5	12
30	The Safety and the Pharmacokinetics and Pharmacodynamics of a Pegylated Interferon Alpha-2a Formulation, Dong-A's DA-3021. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2010, 18, 117.	0.1	1